Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Cabotegravir Pediatric Dispersible Tablet in Healthy Adults
NCT05776108Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Area under the concentration-time curve from time zero extrapolated to infinite time up to 168 hours, Area under the concentration-time curve from time zero extrapolated to last time of quantifiable concentration up to 168 hours and 1 more. Started Mar 2023; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05776108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776108.